Triple-negative breast cancer (TNBC) (ER-negative, progesterone receptor (PR) negative, and HER2-negative) is of particular interest, because it is aggressive and metastatic and does not respond to current therapies. Here, ERBB2 is linked to triple-negative breast carcinoma.